Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
